Best Energy Stocks Based on AI: Returns up to 45.06% in 3 Days
High Short Interest Stocks Based on Machine Learning: Returns up to 107.78% in 7 Days
Top 10 Stocks Based on AI: Returns up to 16.86% in 14 Days
Best Hedge Fund Stocks Based on AI: Returns up to 230.19% in1 Month
High Implied Volatility Based on AI: Returns up to 1186.99% in 3 Months
Top 10 Stocks Based on AI: Returns up to 406.15% in 1 Year
Tenet Healthcare Corporation (THC) is up 8.96% sinceSeptember 23rd, 2025,propelled by exceptional quarterly results, surpassing expectations with a ~74% year-over-year increase in adjusted EPS and significant margin expansion, prompting an upward revision of its full-year 2025 EBITDA outlook to $4.40B–$4.54B and an improved hospital adjusted admissions forecast, propelling its stock price up 8.96% from $193.08 on September 23, 2025, to $210.55 by October 26, 2025, driven by a confluence ofmacroeconomic tailwinds and company-specific catalysts that have reignited investor enthusiasm amid broader market optimism. Favorable healthcare sector dynamics, including stabilizing reimbursement rates and increased demand for elective procedures post-inflationary pressures, have bolstered investor confidence in hospital operators like Tenet, while the company’s strategic focus on higher-acuity cases, optimized payer mix, and cost discipline has amplified its appeal. Under CEO Saum Sutaria, Tenet’s three main segments—Hospital Operations & Other, Ambulatory Care (via United Surgical Partners International), and Support Services (via Conifer Health Solutions)—have capitalized on robust growth drivers, including a surge in high-margin outpatient services through USPI, enhanced operational efficiencies from AI-driven automation at Conifer, and divestitures of underperforming assets to fund high-return investments and an expanded share repurchase program, supported by strong free cash flow. Analyst upgrades, with firms like Zacks and Leerink Partners raising fiscal 2025 EPS estimates by $0.93–$1.49 to ~$15.85 per share ahead of the October 28, 2025, Q3 earnings release, reflect expectations of sustained USPI momentum, stable hospital margins, and a favorable Zacks Rank with a 46% average earnings surprise, driving a technical breakout above key resistance levels. Despite trading at a discount to peers like EHC, UNS, ENSG, SGRY, and CON—with lower P/E (12.40), P/S (0.88), P/B (4.57), and P/CF (6.96) ratios as of September 23, 2025—THC’s valuation suggests a potential 44% upside to a target of $277.43, though analysts’ average target is $201.43 with a predominantly Buy rating. Risks such as labor and supply cost pressures, regulatory challenges in Medicaid/insurance reimbursements, and macroeconomic constraints persist, but Tenet’s focus on admissions growth, ambulatory expansion, and operational efficiency, coupled with a bullish one-year forecast from I Know First’s stock-picking AI, positions it for potential low double-digit upside over the next 12-18 months, provided execution remains robust and costs are managed effectively.
Tesla, Inc. (TSLA) is up 31.69% since September 1st, 2025, propelled by macroeconomic tailwinds and company-specific catalysts fueling investor fervor amid a buoyant market landscape. Anticipation of Federal Reserve interest-rate cuts, signaled by cooling inflation and rising jobless claims, has invigorated high-growth tech stocks like Tesla by slashing borrowing costs for electric vehicle (EV) financing and inflating valuations for autonomy and energy storage, evoking the 2020 surge during near-zero rates. Tesla's Q3 2025 results, unveiled on October 22, boasted record revenue of $28.1 billion—a 12% year-over-year leap crushing Wall Street's $26.4 billion consensus—alongside non-GAAP EPS of $0.50 and $3.99 billion in free cash flow, driven by 497,099 vehicle deliveries (up 7% YoY, turbocharged by U.S. buyers rushing for expiring $7,500 EV tax credits) and 12.5 GWh in energy storage deployments, with the energy segment exploding 67% YoY to claim over 25% of revenue and margins exceeding 30%, offsetting a 6.5% dip in automotive sales amid softening European demand (e.g., 9.4% plunge in German registrations) and competition from BYD. The energy powerhouse, anchored by Megapack surges and the Megablock system slashing installation costs by 40%, has cemented Tesla's pivot to a diversified AI-energy juggernaut, while the Austin robotaxi pilot's expansion from 18 to 170 square miles—complete with Nevada DMV nods for public testing—has ignited mania around Cybercab plans and a 2026 network for private Teslas. Analyst upgrades like Piper Sandler's $500 target, Stifel's Buy retention, and bullish calls from Goldman Sachs and UBS have triggered short squeezes and breakouts past $384 resistance, as TSLA danced above its 20-, 50-, 100-, and 200-day moving averages. Despite YTD woes—a 15% slide masked by a 60% 12-month gain—stemming from Q2's 12% revenue contraction to $92.7 billion, margin squeezes from tariff hikes, and stalled China registrations, Tesla's diverse shareholder base (45% institutional heavyweights like Vanguard, 12% Musk-owned, plus retail hordes on Robinhood) has fueled volatility-turned-victory, with its 186x P/E and 90x EV/EBITDA reflecting faith in AI-robotics over auto fragility. Risks loom—regulatory probes into crash reporting, post-tax-credit demand cliffs, and execution stumbles versus Waymo's operator-free rides—but with institutional rebounds, a Zacks-like earnings surprise history, and I Know First's dark-green one-year bullish signal, Tesla's trajectory screams low-double-digit upside through 2025-2030.
Apple Inc (AAPL) is up 1383% since August 18th, 2025, driven by a blend of macroeconomic tailwinds and company-specific developments that have rekindled investor optimism amid a favorable market environment. Apple’s Q2 FY2025 results reported revenue of $90.75 billion, down 4% year-over-year due to softer iPhone and Mac sales, but the company’s robust Services segment, with a record-high 75% gross margin, and a $100 billion share buyback authorization bolstered confidence in its financial resilience. Macroeconomic factors, particularly expectations of Federal Reserve interest-rate cuts signaled by cooling inflation, have lifted high-growth tech stocks, reducing borrowing costs for consumers and enhancing valuations for Apple’s long-term AI and supply chain initiatives, echoing the 2020 tech rally. Apple’s aggressive pivot to a U.S.-based supply chain, targeting over 19 billion domestically sourced chips in 2025 through partnerships with TSMC, Amkor, Texas Instruments, GlobalFoundries, and Corning, has mitigated tariff risks and positioned the company for potential cost advantages, especially as competitors like Samsung and Lenovo lag in domestic production. Technically, AAPL’s rebound from April 2025 lows, reclaiming its 50-day and 200-day moving averages, has fueled bullish momentum, though it remains just below the critical $234–$238 resistance zone, with a breakout pending to confirm a full trend reversal. Despite challenges—rising U.S. supply chain costs, a one-time $15.4 billion EU tax settlement in H1 2025, and regulatory uncertainties around tariff exemptions—Apple’s strategic shift toward Services (now a larger revenue contributor), AI infrastructure investments, and a negative retained earnings balance due to massive buybacks reflect a structural evolution that supports long-term growth. Analyst sentiment is mixed, with MarketWatch noting a Hold consensus but Yahoo Finance highlighting Buy recommendations, with price targets ranging from $139 to $315, while I Know First’s stock-picking AI signals a strong bullish one-year outlook. Risks remain, including potential margin pressure from U.S. fab inefficiencies and concentrated supplier risks, but Apple’s diversified revenue streams, buyback-driven EPS growth, and technical recovery position it for potential low-double-digit upside if it breaks above $238, particularly as Q3 FY2025 earnings loom on October 30, 2025, potentially catalyzing further gains if Services momentum and supply chain progress impress.
I Know First's Multi-Tier Strategy leverages an advanced AI self-learning algorithm to forecast stock market directions using S&P 500 stocks selected via predictability filters, focusing on GICS Level 1 and 2 ETFs along with individual stocks for long or short positions based on majority forecast signals. From January 1, 2020, to July 31, 2025, this monthly rebalanced strategy delivered a 561.18% return, surpassing the S&P 500 by 465.08%, with strong risk-adjusted metrics including a Sharpe ratio of 1.54 and Sortino ratio of 2.28.
Strategy Construction: Determines majority direction (long if more bullish forecasts, short if bearish) and allocates 60% to top three Level 1 sector ETFs, 10% to top two Level 2 industry ETFs, 20% to five most predictable stocks, and 10% to SPY or OEF based on signal strength.
AI Algorithm Foundation: Employs machine learning, chaos theory, and fractals to analyze non-linear market factors, ranking inputs by significance, testing models on 15 years of data, and daily refining without human bias for over 13,500 markets.
Performance Highlights: Achieved exceptional annual returns across years, demonstrating resilience and outperformance in various market conditions.
Institutional Focus: Offered as a tier 2 service to hedge funds, banks, and investment houses, with personalized solutions enhancing client investment processes.
This multi-tier approach underscores I Know First's commitment to data-driven, adaptive forecasting that provides institutional investors with a robust edge in navigating complex market dynamics.
Webinar Replay - Last Chance To Take Advantage Of The Deals
At I Know First, we continue empowering investors with cutting-edge AI forecasting tools that consistently outperform the market. Following our latest live webinar hosted by CEO Yaron Golgher and Head of Advisory Ben Rubin, we’re offering three exclusive limited-time deals designed for investors who want to stay ahead.
Deal #1: 1 + 1 Webinar Special Deal
Get two powerful AI stock packages for the price of one. Ideal for both long and short-term investors seeking actionable forecasts and smarter trading signals powered by institutional-grade AI insights. Get this deal
Access our Top 10 AI-Selected Stocks Portfolio, rebalanced every 4 weeks by our proprietary algorithm. Gain exposure to high-performance equities backed by data-driven analysis and automated optimization. Subscribe here
Deal #3: Extra Package of Your Choice + AI Portfolio
Get our complete AI-Powered Portfolio combined with a premium institutional-level forecast package for comprehensive, AI-driven investment coverage. Perfect for professionals and advanced investors. Activate this plan
These AI-powered promotions empower investors with timely, specialized stock selections to navigate 2025's dynamic markets effectively.
The I Know First AI Portfolio, previously an institutional offering now available to retail investors, leverages advanced machine learning and quantitative analysis to identify high-potential stocks. Designed to deliver market-beating returns, this portfolio uses proprietary deep learning algorithms to create a monthly-rebalanced, long-only stock selection aimed at outperforming the market.
Since its inception, the I Know First AI Portfolio has achieved a +36.45% return, significantly surpassing the S&P 500’s +19.76% return, resulting in a +16.69% alpha. This performance highlights the portfolio’s ability to generate resilient investment strategies, even in volatile market conditions, showcasing the power of AI-driven investing.
The portfolio’s specific stock picks are exclusive to subscribers, ensuring the integrity of the signals and providing a competitive edge. Retail investors and experienced traders alike can access these institutional-grade tools by subscribing, gaining entry to the next AI-generated portfolio before the monthly rebalancing.
Stock Picking Strategies and Trading Methods with I Know First Algorithm
The I Know First algorithm employs AI and machine learning to generate empirical stock forecasts across multiple time horizons, emphasizing predictability (correlation confidence from -1 to 1) and signal (predicted price deviation) to guide long and short positions without human bias. Investors can enhance decision-making through strategies like assessing forecast consistency across time frames and packages, aligning with general market trends, exercising patience for verification, and timing exits around volatility or news events, paired with trading techniques ranging from passive holding to integrated risk-return balancing.
Algorithm Fundamentals: Utilizes neural networks and genetic algorithms for self-learning predictions on over 10,500 assets, continuously refining models based on historical data to output daily forecasts for short- (3 days) to long-term (1 year) horizons.
Forecast Interpretation: Prioritize high predictability for reliability and strong signals for magnitude; use color-coded tables (green for bullish, red for bearish) to gauge overall market sentiment, such as a bearish tilt if most assets show negative directions.
Stock Picking Best Practices: Seek consistency in asset appearances across time frames/packages for validation (e.g., bullish in all horizons strengthens short-term buys); monitor indices like S&P 500 for trends, wait for next-day confirmation, and exit volatile positions post-forecast or before major news releases.
Trading Techniques: Options include passive (buy-and-hold full period), conservative (top predictability only), trend signal (highest signals for returns), integrated (filter by predictability then signals for balance), and short-term (trade while assets rank high in volatile packages).
This comprehensive framework equips traders and institutions with adaptive, data-driven tools to outperform markets by combining algorithmic insights with disciplined strategies.
Eli Lilly achieved over 40% revenue growth in the first half of 2025, fueled by blockbuster GLP-1 drugs Mounjaro and Zepbound that drove nearly three-quarters of total revenue from cardiometabolic therapies, amid confident management guidance raised to $60–62 billion for the full year. While facing supply bottlenecks, pricing pressures, and competition primarily from Novo Nordisk, the company boasts superior profitability metrics, a premium valuation reflecting pipeline potential, and bullish technical indicators positioning it as a strong buy for growth investors.
Year-to-Date Momentum: Q1 revenue hit $12.7 billion (+45% YoY) with non-GAAP EPS of $3.34, followed by Q2 at $15.6 billion (+38% YoY), net income of $5.7 billion, and diluted EPS nearly doubling to $6.29, supported by expanding GLP-1 demand despite pricing headwinds.
Revenue Composition: Product sales comprised 94.65% of Q2 revenue, with cardiometabolic segment at 72.91% led by Mounjaro and Zepbound generating $8.58 billion (55% of total); oncology contributed 15.5% via Verzenio, and immunology 8.1% through Taltz.
Geographic Breakdown: U.S. markets dominated with $10.81 billion (69.5%) in Q2, while ex-U.S. added $4.74 billion (30.5%), including 38% YoY growth in Q1 non-U.S. revenue; Europe represented 15–16%, with China and Japan each at 3–4%.
Key Products and Rivals: Star performers include Mounjaro (diabetes) and Zepbound (obesity/sleep apnea), plus Kisunla (Alzheimer’s) and pipeline hopeful orforglipron (oral GLP-1); primarycompetitor Novo Nordisk leads in semaglutide drugs, with Biogen/Eisai in neurology and Roche/Pfizer/Merck in oncology/immunology.
Financial Strength and Challenges: Trailing net profit margin at 25.9%, operating margin 45.8%, ROE 86%, outperforming peers like Novo (30–35% margins); risks encompass manufacturing scaling delays, FDA compliance issues at sites, regulatory pricing scrutiny, and compounding pharmacy competition.
Valuation and Technical Outlook: Trades at elevated multiples (P/S ~14x vs. Novo’s 4.9x, P/E >50x) above sector norms of 8–10x EV/revenue, justified by growth; 52-week performance shows mild decline vs. peers' tumbles, with bullish Bollinger Bands, RSI exiting overbought, and reduced volatility signaling an entry point.
As Q3 earnings approach on October 30, 2025, Eli Lilly's innovation-driven trajectory and high-demand franchises solidify its appeal as a balanced growth play in the pharmaceutical landscape.
Another week of strong market momentum has passed, validating the systematic, data-driven approach we champion at I Know First. While major indexes notched their second winning week, with the S&P 500 now up an impressive 15% for the year and the Nasdaq up 20%, the real story remains finding the asymmetrical opportunities that drive truly differentiated returns.
We want to highlight IESC, which delivered an outstanding performance thanks to a powerful combination of signal and predictability from our AI-driven model. Selected for our AI-Powered Portfolio for the May–September period based on strong algorithmic indicators, IESC has substantially out-paced the broader market over that time. Notably, last Friday the stock jumped approximately +14.5%
The Engine of Outperformance: Our Self-Learning AI
At the core of I Know First is our proprietary, self-learning algorithm - a system built to predict market flow by separating predictable information from "random noise." Our technology is not a static model; it is a dynamic ecosystem of Artificial Intelligence and Machine Learning, constantly evolving to maintain its predictive edge.
A critical component of this system is the integration of Genetic Algorithms. Much like natural selection, these algorithms constantly propose millions of trading "theories" and hypotheses, testing them on decades of historical market data. Only the models that demonstrate sustained predictive accuracy are allowed to survive and propagate. This purely empirical, non-biased approach allows our system to adapt rapidly to changing market conditions and uncover subtle, complex relationships between over 13,500 financial assets, far beyond the capabilities of human analysis.
Webinar Recap: Beat the Market with AI
Thank you to everyone who joined our exclusive webinar last week. The session provided a deep dive into optimizing trading strategies using our system’s Signal and Predictability indicators. If you missed it, or wish to review the actionable insights, you can watch the replay here: Watch the Replay Here:
Spotlight: Quantum Computing—The Government’s Next Priority
The strategic importance of Quantum Computing was highlighted this week with reports that the Trump Administration is in talks to take equity stakes in quantum-computing firms in exchange for federal funding. This unprecedented move signals a new era of public investment in critical, high- growth, national-security-relevant technology.
This is precisely the kind of strategic shift our AI is built to anticipate and exploit. Our system is screening the entire U.S. market, identifying the best opportunities within this unique universe. The results speak for themselves:
This dedicated Quantum Computing package is available only as part of our exclusive Webinar 1+1 Deals. Secure your access now: Portfolio Update: Monthly AI Rebalancing Claim Your 1+1 Deal
Turning Forecasts Into Action: Recent AI Successes
Our self-learning system continues to deliver exceptional performance across various market sectors and strategies. Here are just a few of the recent forecast successes generated by our AI:
If you want to stay ahead of the next market rotation and capitalize on high- potential sectors like Quantum Computing, now is the time to let our AI do the heavy lifting for your portfolio.
Daily AI Forecasts—6 Time Frames Access full ranked signal lists across six time horizons, updated daily. Get Daily Forecasts:
Final Thought: Opportunity Never Sleeps - and Neither Does AI Every day, our AI scans thousands of assets across global markets - flagging the next high-momentum stocks, breakout opportunities, and reversal setups long before they appear in headlines.
This is where the edge lives: not in guessing, but in knowing first.
Warm regards, Yaron Golgher CEO, I Know First
I Know First Most Popular Package Of The Week
Top 10 Stocks Forecast Package
Includes daily forecasts for:
Top 10 Stocks + S&P500 Forecast for long and short positions.
6 time ranges: 3 days, 7 days, 14 days, 1 month, 3 months and 1 year
Investment universe: US stocks.
Check some recent forecasts' performances: 14 Days, and 3 Months!
Apple's iPhone 17 series kicked off strongly on October 23, 2025, with sales surging 14% over the iPhone 16 in the first 10 days across the US and China, where the standard model's enhanced chip, display, memory, and front camera at the same price drove nearly doubled demand; the Pro Max benefited from $100 US operator subsidies, while the iPhone Air edged ahead of last year's despite a China launch delay, signaling a more successful cycle overall. However, weak interest prompted Apple to slash iPhone Air production by one million units and boost iPhone 17 output by two million, as a KeyBanc survey revealed negligible demand for the folding model amid reluctance to pay premiums and minimal AI influence on purchases, echoing Samsung's cancellation of its Galaxy S25 Edge successor. Diversifying supply chains, Apple is shifting Vision Pro assembly (now with M5 chip and Dual Knit headband) to Vietnam from China, alongside producing US-bound devices there, iPhone 17s in India, increasing Mac builds in Thailand and Malaysia, and iPhone/Apple Watch glass in the US.
